within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AX13_UridineTriacetate;

model UridineTriacetate
  extends Pharmacolibrary.Drugs.ATC.A.A16AX13;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A16AX13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Uridine triacetate is an orally administered prodrug of uridine used as an antidote for overdose or toxic reactions to fluorouracil or capecitabine chemotherapy. It is FDA-approved for emergency treatment within 96 hours of such overdoses or toxicity. Its pharmacological effect relies on increasing uridine levels to counteract toxicity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adults based on published summaries and secondary references. No detailed PK study found with population or compartmental parameters.</p><h4>References</h4><ol><li><p>Ashour, OM, et al., &amp; el Kouni, MH (2000). Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2&#x27;,3&#x27;,5&#x27;-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy. <i>Cancer chemotherapy and pharmacology</i> 46(3) 235–240. DOI:<a href=&quot;https://doi.org/10.1007/s002800000138&quot;>10.1007/s002800000138</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11021741/&quot;>https://pubmed.ncbi.nlm.nih.gov/11021741</a></p></li><li><p>Kelsen, DP, et al., &amp; Bertino, J (1997). Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 15(4) 1511–1517. DOI:<a href=&quot;https://doi.org/10.1200/JCO.1997.15.4.1511&quot;>10.1200/JCO.1997.15.4.1511</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9193347/&quot;>https://pubmed.ncbi.nlm.nih.gov/9193347</a></p></li><li><p>Hidalgo, M, et al., &amp; Rowinsky, EK (2000). Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 18(1) 167–177. DOI:<a href=&quot;https://doi.org/10.1200/JCO.2000.18.1.167&quot;>10.1200/JCO.2000.18.1.167</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10623707/&quot;>https://pubmed.ncbi.nlm.nih.gov/10623707</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end UridineTriacetate;
